These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 2215516

  • 1. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y, Zighelboim J, Berek JS, Bonavida B.
    Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
    [Abstract] [Full Text] [Related]

  • 2. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers.
    Nio Y, Zighelboim J, Berek JS, Bonavida B.
    Anticancer Res; 1990; 10(2A):441-6. PubMed ID: 2346317
    [Abstract] [Full Text] [Related]

  • 3. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ, Krosnick JA, Rosenberg SA.
    J Immunol; 1989 Jan 15; 142(2):726-33. PubMed ID: 2783444
    [Abstract] [Full Text] [Related]

  • 4. Lymphokine-activated effector cells: modulation of activity by cytokines.
    Mehta S, Flanagan P, Blackinton D, Wanebo H.
    Lymphokine Cytokine Res; 1992 Apr 15; 11(2):73-7. PubMed ID: 1581419
    [Abstract] [Full Text] [Related]

  • 5. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH, Withrow SJ, Johnston MR, Kruse CA.
    Am J Vet Res; 1991 Jul 15; 52(7):1132-6. PubMed ID: 1892269
    [Abstract] [Full Text] [Related]

  • 6. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP, Blanchard DK, Duan C, Roberts WS, Cavanagh D, DeCesare S, Djeu JY.
    J Soc Gynecol Investig; 1995 May 15; 2(6):762-71. PubMed ID: 9420887
    [Abstract] [Full Text] [Related]

  • 8. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M, Hasegawa H, Nakayabu M, Fukai K, Suzuki S.
    J Clin Lab Immunol; 1993 May 15; 40(2):47-60. PubMed ID: 7932628
    [Abstract] [Full Text] [Related]

  • 9. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
    Dannemann BR, Morris VA, Araujo FG, Remington JS.
    J Immunol; 1989 Oct 15; 143(8):2684-91. PubMed ID: 2477453
    [Abstract] [Full Text] [Related]

  • 10. [Effect of malignant ascitic fluids and OK-432 on the induction of LAK activity in peripheral blood mononuclear cells of gynecological cancer patients].
    Kanaoka Y, Umesaki N.
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jun 15; 43(6):611-8. PubMed ID: 1856521
    [Abstract] [Full Text] [Related]

  • 11. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA, Vujanovic NL, Herberman RB, Hiserodt JC.
    J Immunol; 1988 Apr 15; 140(8):2846-52. PubMed ID: 3258622
    [Abstract] [Full Text] [Related]

  • 12. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun 15; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD, Economou JS, Shau H, Golub SH.
    J Surg Res; 1993 Nov 15; 55(5):486-92. PubMed ID: 8231167
    [Abstract] [Full Text] [Related]

  • 15. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB, Itoh K, Balch CM.
    J Immunol; 1987 Feb 15; 138(4):1068-73. PubMed ID: 3100627
    [Abstract] [Full Text] [Related]

  • 16. Kinetic analysis of human IL-2 activated cytotoxic cells.
    LeFever AV, Piaskowski VD, Casper JT, Truitt RL.
    Immunopharmacol Immunotoxicol; 1991 Feb 15; 13(1-2):147-68. PubMed ID: 1770217
    [Abstract] [Full Text] [Related]

  • 17. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N, Ozaki A, Ishihara J, Sakurai M, Sasaki Y, Takahashi H, Sano T, Hoshi A.
    Gan To Kagaku Ryoho; 1986 Apr 15; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [Abstract] [Full Text] [Related]

  • 18. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV, Ludwig WD, Thiel E.
    Nat Immun; 1992 Apr 15; 11(3):117-32. PubMed ID: 1392400
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
    Yun YS, Hargrove ME, Ting CC.
    J Immunol; 1988 Aug 15; 141(4):1390-7. PubMed ID: 3260924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.